BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Rare metabolic and lysosomal diseases clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for lysosomal storage diseases: 111 (51 sponsors; 15 newly posted in the last 180 days, 5 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 21.6, rank 23 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 5, Phase 2 35, Phase 3 34, Phase 4 4, N/A 33.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Sanofi SNY | 7 | P3 5, NA 2 | 1 | 0 |
| Azafaros B.V. | 6 | P3 4, P2 2 | 2 | 0 |
| JCR Pharmaceuticals Co., Ltd. | 7 | P2 3, P3 3, NA 1 | 1 | 1 |
| Amicus Therapeutics | 6 | NA 3, P3 3 | 0 | 2 |
| Chiesi Farmaceutici S.p.A. | 5 | P3 2, NA 3 | 0 | 0 |
| Denali Therapeutics Inc. DNLI | 5 | P3 2, P2 3 | 0 | 0 |
| REGENXBIO Inc. RGNX | 4 | P3 2, NA 2 | 0 | 0 |
| Ultragenyx Pharmaceutical Inc RARE | 4 | P3 2, NA 2 | 1 | 0 |
| Orchard Therapeutics | 3 | P2 1, P3 2 | 0 | 0 |
| QED Therapeutics, a BridgeBio company | 5 | NA 1, P2 3, P3 1 | 0 | 1 |
| Takeda TAK | 3 | P3 1, NA 2 | 0 | 0 |
| Spur Therapeutics | 2 | P2 1, P3 1 | 0 | 0 |
| AO GENERIUM | 1 | P3 1 | 0 | 0 |
| CANbridge Life Sciences Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Idorsia Pharmaceuticals Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| IntraBio Inc | 1 | P3 1 | 0 | 0 |
| Regeneron Pharmaceuticals REGN | 1 | P3 1 | 0 | 0 |
| Spruce Biosciences SPRB | 1 | P3 1 | 0 | 0 |
| Genzyme, a Sanofi Company | 7 | NA 4, P4 2, P2 1 | 0 | 0 |
| Prevail Therapeutics | 3 | P2 3 | 0 | 1 |
| Shionogi | 3 | P1 1, P2 2 | 2 | 0 |
| 4D Molecular Therapeutics FDMT | 2 | P2 2 | 0 | 0 |
| Astellas Gene Therapies | 2 | NA 1, P2 1 | 0 | 0 |
| GC Biopharma Corp | 2 | P1 2 | 0 | 0 |
| Phoenix Nest | 2 | NA 2 | 1 | 0 |
New-entrant sponsors: CANbridge Life Sciences Ltd., Idorsia Pharmaceuticals Ltd..
Recently stopped trials
- NCT04040049 Spur Therapeutics - terminated: Freeline has decided to pause development of FLT190 in Fabry disease to focus its resources on advancing FLT201. A Fabry Disease Gene Therapy Study
- NCT04455230 Spur Therapeutics - terminated: The study was suspended early due to a corporate financial decision. A final SAP was written to specify the impact on final outcome measurem A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
- NCT04628871 Sangamo Therapeutics - terminated: Sangamo declared Chapter 11 Bankruptcy on 23Jun2026 and terminated the study on 21Jul2026. Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
- NCT07455864 AstraZeneca - terminated: This decision is based on a reassessment of the current need for this study, impracticality of opening study sites in outpatient clinics due Lysosomal Acid Lipase Deficiency in Risk Groups
- NCT04771416 Gemma Biotherapeutics - suspended: The study was stopped due to changes in the company strategy. Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P1/P2 | GeneCradle Inc | NCT06391736 Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug | Pompe Disease (Late-onset) | recruiting | 33 |
| 2026-12-31 est. | P2 | JCR Pharmaceuticals Co., Ltd. | NCT03708965 An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II | Mucopolysaccharidosis II | active not recruiting | 19 |
| 2026-12-31 est. | P3 | Amicus Therapeutics | NCT04020055 A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | Fabry Disease | active not recruiting | 14 |
| 2027-02 est. | P1/P2 | Prevail Therapeutics | NCT04411654 Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE) | Gaucher Disease, Type 2 | active not recruiting | 7 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-30 est. | P2 | Genzyme, a Sanofi Company | NCT02843035 Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension | Gaucher Disease Type 1; Gaucher Disease Type 3 | active not recruiting | 12 |
| 2026-08-31 | P3 | Idorsia Pharmaceuticals Ltd. | NCT03737214 A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease | Fabry Disease | completed | 107 |
| 2026-08-10 est. | P1/P2 | ModernaTX, Inc. | NCT06147856 A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria | Phenylketonuria | withdrawn | |
| 2026-07-21 | P3 | PTC Therapeutics PTC | NCT05166161 A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria | Phenylketonuria | completed | 247 |
| 2026-06 est. | P1/P2 | 4D Molecular Therapeutics FDMT | NCT05629559 4D-310 in Adults With Fabry Disease and Cardiac Involvement | Fabry Disease | recruiting | 18 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "lysosomal storage diseases"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.